Our History

2011	Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions. Emervel (dermal filler range) launch in Europe and Latin America. Launch of Cetaphil Restoraderm. Plant extensions in France and Canada.

2010	Differin Lotion 0.1% (acne) launch in the United States. Galderma hits the 1 billion mark in sales.

2009	Launch of Azzalure (glabellar lines) and Oracea in Europe. Vectical (psoriasis) launch in the United-States. Oracea

2008	Epiduo (acne) launch. Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea). Launch of Differin 0.1% in Japan. Differin

2007	Licensing agreements for a botulinum toxin type A and Pliaglis (topical anesthetic). Differin 0.3% launch. Pliaglis

2006	Clobex Spray launch in the US. Opening of the new R&D center in Sophia Antipolis, France.

2005	Metrogel 1% (rosacea) launch in the United-States. For the first time, Galderma ranks Number One in D class in its markets (source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).

2004	Opening of a new production site in Hortolandia, Brazil. Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.

2003	Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US.

2002	Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan. First FDA approvals for pharmaceutical production in Montreal.

2001	Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment). Launch of Clindagel (anti-acne).

2000	The Montreal production unit comes on stream. Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).

1999	Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.

1998	Inauguration of a new R&D facility in Princeton, New Jersey, USA. Acquisition in Brazil of Darrow’s dermatology portfolio.

1997	Acquisition of Basotherm, a subsidiary of Boehringer.

1996	Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.

1995	Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.

1994	Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.

1993	Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.

1989	Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.

1988	Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.

1986	Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.

1981	Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.

1979	L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.

1977	Nestlé acquires Alcon to strengthen its presence in the North American market.

1972	Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.

1961	Creation of the Owen dermatology company in Dallas, Texas, USA.